Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible.
Company profile
Ticker
LOXO
Exchange
Website
CEO
Joshua H. Bilenker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
LOXO stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
25 Feb 19
EFFECT
Notice of effectiveness
22 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
8-K
Completion of Acquisition or Disposition of Assets
15 Feb 19
POSASR
Automatic shelf registration (post-effective amendment)
15 Feb 19
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Loxo Oncology, Inc.
8 Jan 20
SC 13D/A
Loxo Oncology, Inc.
15 Feb 19
SC 13D/A
Beneficial ownership report (amended)
15 Feb 19
4
Naarden Jacob Van
15 Feb 19
4
Nisha Nanda
15 Feb 19
4
Avi Z. Naider
15 Feb 19
4
TIMOTHY M MAYLEBEN
15 Feb 19
4
Lori Anne Kunkel
15 Feb 19
4
Steve Harr
15 Feb 19
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|